Vivendi shares fall 4% as first-half earnings hit by restructuring costs

Vivendi shares fell 4% after first-half adjusted EBITA dropped to €4m from €18m, with a €21m net cost from a collective headquarters termination plan implemented June 1. Revenue for the six months fell 3.5% to €140m, while Vivendi said EBITA would have been €25m excluding termination costs. Investment portfolio value declined to €5.12bn (from €5.88bn at Dec. 31, 2025), and Vivendi paid €92m in total dividends (down from €115m).

Analysis

The market should read this as a NAV and cash-yield problem, not an operating turnaround. The HQ cuts help the corporate line, but the bigger driver is that the holding-company cushion is getting thinner: lower portfolio value and lower dividend intake reduce the margin of safety that usually supports a conglomerate discount. That makes the equity more sensitive to any further weakness in UMG, which is the cleanest near-term proxy for Vivendi’s intrinsic value.

Second-order, the restructuring is mildly positive for long-term overhead efficiency, but it is unlikely to re-rate the stock unless management shows a credible path to simplifying the structure or monetizing assets. The risk is that investors extrapolate one-off savings while ignoring that the consolidated cash engine is still mostly external holdings, so market value will keep tracking music/media multiples rather than the internal P&L. In that setup, stable Gameloft improvement is not enough to offset portfolio mark-to-market pressure.

Over 1-3 months, the key catalyst is any reversal in UMG sentiment or evidence of asset sales that narrow the discount to sum-of-parts. Over 6-18 months, the more important issue is whether Vivendi continues to behave like a passive holdco with recurring execution costs; if so, the discount can stay structurally wide. The contrarian miss is that the one-off termination charge may obscure that recurring corporate savings are improving, so the stock may be less broken operationally than the headline implies.

Key Decisions for Investors

• Short VIVHY/UNVGY into strength versus long UMG (Euronext: UMG): best expressed as a relative-value trade over 1-3 months if the market keeps re-pricing UMG weaker than the operating assets; stop if UMG stabilizes and Vivendi announces a value-accretive simplification or asset sale.
• If already long UMG, use VIVHY weakness to hedge holdco exposure rather than adding outright Vivendi risk; the thesis is that Vivendi's equity behaves like a levered NAV wrapper with limited upside until the discount narrows.
• Avoid chasing a turnaround long in Vivendi until the next catalyst: a cleaner capital-allocation framework, a disposal, or evidence that recurring corporate savings fully offset portfolio income erosion; otherwise risk/reward is poor versus better-quality European media exposures.
• Set a watch level on the implied holdco discount: if Vivendi trades at a materially wider discount to listed stake value after the next portfolio mark, the stock may become interesting for event-driven investors; if not, there is no urgency to buy the dip.